Dietary lutein intake is postulated to interfere with the development of age-related macular degeneration (AMD). Because egg yolkderived lutein has a high bioavailability, long-term consumption of lutein-enriched eggs might be effective in preventing AMD development, but alternatively might increase cardiovascular disease risk. Here, we report the effect of 1-y daily consumption of a buttermilk drink containing 1.5 lutein-rich egg yolks on serum lipid and lipoprotein and plasma lutein concentrations. Additionally, subgroups that could potentially benefit the most from the intervention were identified. Men and women who had early signs of AMD in at least 1 eye, but were otherwise healthy, participated in a 1-y randomized, placebo-controlled parallel intervention trial.
Introduction
Eggs provide several essential nutrients to the diet, such as highquality proteins, minerals, folate, and vitamins A, B-12, D, and K (1). In addition, 1 egg yolk contains on average 200 mg dietary cholesterol, which makes eggs a main contributor of dietary cholesterol intake. The AHA guidelines state that daily dietary cholesterol intake should not exceed 300 mg in healthy individuals (2) , whereas for high-risk individuals, the recommended daily dietary cholesterol intake is even lower (<200 mg) (3) . Consuming elevated amounts of dietary cholesterol was linked to an increase in the ratio of total to HDL cholesterol (4) , suggesting an increased cardiovascular disease (CVD) 7 risk. Furthermore, a recent study suggests that participants with elevated intestinal cholesterol absorption (so-called absorbers) especially are at risk of CVD and not so much those with a high endogenous cholesterol synthesis (5) . Interestingly, Herron et al. (6) reported an increase in large LDL particles and a decrease in small LDL particles after increased dietary cholesterol intake from eggs, which is expected to result in a lower CVD risk. This illustrates that it is difficult to translate results into risk predictions. A possible reason for this could relate to the relatively short follow-up period of most interventions with typical durations ranging from 3 to 20 wk. Therefore, long-term, prospective follow-up studies should be able to provide more consistent answers. Surprisingly, 2 recent long-term studies reported completely opposite conclusions regarding the association between egg consumption and CVD risk (7, 8) . This could relate to the assumption that it is difficult to associate CVD risk with a single nutrient or food product because of the methodologic constraints of such an approach (9) . In addition, it is generally accepted that it is difficult to estimate food intake over longer periods of time (10) . Therefore, to overcome these issues, long-term, well-controlled, double-blind intervention studies could potentially provide the best estimation of changes in CVD risk.
Providing answers to the question of whether frequent egg intake should be discouraged or not is extremely relevant, especially because lutein and zeaxanthin from egg yolks is highly bioavailable (11) , and these carotenoids are suggested to play a role in the prevention or treatment of specific diseases (12) . Lutein from egg yolks has a high bioavailability translating into increased plasma lutein concentrations (11) . Within the circulation, lutein is primarily transported in HDL particles (13) to different target tissues such as the macular region of the retina (14) . Consequently, a higher dietary lutein intake increases macular pigment optical density (MPOD). Both lutein and zeaxanthin are thought to play an important role in preserving the functional integrity of the retina because these are major constituents of the macular pigment (15, 16) . In other words, increased dietary consumption of these carotenoids might have a preventive effect on the risk of agerelated macular degeneration (AMD). If true, this could be of great clinical and societal value because AMD is the most frequent cause of blindness in elderly individuals in the Western world (17) and severely lowers quality of life (18) . Therefore, the primary objective of the present study was to assess the effects of 1-y daily consumption of lutein-rich egg yolks on plasma lutein concentrations, MPOD, and visual function in participants with early AMD (to be reported elsewhere). The secondary objective-as discussed in this paper-was to evaluate the effects of long-term daily egg yolk consumption on serum lipids and lipoproteins to estimate changes in CVD risk. Moreover, because it is well known that there is a large interindividual variation of dietary cholesterol absorption ranging from 20% to 70% (19) and that participants can be classified as being cholesterol absorbers or synthesizers (20, 21) , we also tried to see whether we could identify more or less responsive subgroups. Another typical example of such a subgroup could be based on the APOE genotype because the relation between APOE genotype and cholesterol metabolism is well known (22, 23) . Interestingly, the APOE genotype also seems to be related to the risk of developing AMD (24) ; however, to the best of our knowledge, it is not known whether the APOE genotype influences lutein metabolism.
Participants and Methods
Participants. The Medical Ethics Committee of Maastricht University Medical Center approved the study protocol. A total of 101 participants were recruited via advertisements in newspapers in the province of Limburg, The Netherlands. All participants gave their written informed consent before the screening procedure started. Eligible participants were at least 50 y of age, did not receive treatment for diabetes or elevated serum cholesterol concentrations, and had early signs of macular degeneration, as evidenced by drusen and/or retinal pigment epithelium alterations in at least 1 eye through fundus photography. Furthermore, intake of dietary supplements containing lutein or zeaxanthin was not allowed, and participants allergic to eggs or egg products were not included.
Twelve participants withdrew during the 1-y follow-up of the study. Of these participants, 6 were part of the experimental (Egg) group and 6 were part of the control (Con) group. One participant started lutein supplementation during the intervention, 2 participants started cholesterol-lowering treatment via their general practitioner, 4 participants suffered from digestive tract complaints after consuming the drinks (2 in the Con group and 2 in the Egg group), and 4 participants withdrew because of various other physical complaints or personal reasons. Because complaints were equally distributed over the Con and Egg groups, we assumed that there was no relation with the experimental study product.
A total of 29 men and 60 women completed the study. One participant, who was part of the intervention group, was left out of analysis because of outlying HDL cholesterol concentrations, as evidenced by a large CookÕs distance. Final statistical analyses were performed on data from 88 participants. The flow of participants throughout the entire study follow-up is shown in Figure 1 .
Study design and intervention. Participants were recruited for a randomized, double-blind, placebo-controlled 1-y dietary intervention trial. Before the start of the study, participants were randomly assigned to either the Egg or the Con group. Participants who were allocated to the Egg group were asked to consume a lutein-enriched egg drink daily (provided by Newtricious R&D). The egg yolks used in the production of these drinks were enriched with lutein, through natural sources, via the feed of laying hens. The feed never exceeded the European Union regulation concerning the maximal xanthophyll concentration of 80 mg/kg. One-and-a-half egg yolks were incorporated into an 80-mL buttermilk drink, i.e., the drink provided a mean of 1.4-mg lutein and 323-mg cholesterol/d for a total follow-up period of 1 y. Participants in the Con group were administered a comparable buttermilk drink, without the addition of egg yolks. The nutrient composition of the 2 drinks is provided in Supplemental Table 1. So that participants were unaware of treatment groups, the color of the control drink was matched to that of the lutein-enriched egg drink by adding synthetic colorants E104 and E110. Every 2 wk fresh products were delivered to participantsÕ homes. At baseline and at the end of the intervention period, participants were asked to fill out a validated FFQ. These questionnaires were immediately checked by the research dietician and used to calculate energy and nutrient intakes by the Dutch food composition table. Participants were asked not to make large changes in their dietary pattern, level of physical exercise, use of alcohol, and smoking habits during the 1-y course of the study.
Blood sampling and analyses. At the start and end of the intervention period (after 12 mo), blood samples were taken after an overnight fast. Blood was sampled into serum separator tubes (Becton, Dickinson and Company) for analysis of lipids, apos, and high-sensitivity C-reactive protein (hsCRP). These tubes were placed at room temperature for at least 30 min to allow clotting, followed by low-speed centrifugation at 1300 3 g for 15 min at 21°C to obtain serum. Fasting serum samples were enzymatically measured to determine serum total cholesterol by the cholesterol oxidase phenol + aminophenazone (CHOD-PAP) method (Roche Diagnostics), as well as HDL cholesterol (precipitation method; Roche Diagnostics) and TG concentrations, with correction for free glycerol (GPO Trinder; Sigma-Aldrich). ApoB100, apoA1, and hsCRP were analyzed by highly sensitive immunoturbidimetric assays (Horiba ABX). Serum LDL concentrations were calculated according to the Friedewald equation (2) . Liver and kidney function variables [creatinine, alkaline phosphatase (ALP), g-glutamyltransferase, aspartate aminotransferase, alanine transaminase, and total bilirubin] were measured in Effect of egg yolk dairy drink on serum lipids 1371 serum on a Beckman Coulter Synchron LX20 PRO Clinical System (Beckman Coulter). A list of markers reflecting intestinal cholesterol absorption (sitosterol, campesterol, and cholestanol) and endogenous cholesterol synthesis (lathosterol) also were analyzed in serum by GC-MS as described before (25) .
Plasma was obtained by sampling blood into EDTA or sodium fluoride (NaF) tubes (Becton, Dickinson and Company), followed by low-speed centrifugation at 1300 3 g for 15 min at 4°C. Lutein and zeaxanthin concentrations were determined in EDTA plasma samples by HPLC as described (26) . NaF plasma was used for analyzing circulating glucose concentrations (Horiba ABX). The nonesterified FA (NEFA) concentrations also were analyzed in fasted NaF plasma (NEFA kit; WAKO Chemicals).
Immediately after centrifugation, both serum and plasma samples were snap-frozen in liquid nitrogen and stored at 280°C until analysis. All indicated measurements were performed in the same assay to reduce interassay variation. APOE genotyping. DNA was collected from 87 participants who completed the study. DNA was isolated from the buffy coat layer of 10-mL blood collected in an EDTA-containing tube (Becton, Dickinson and Company). The rs7412 and rs429358 single nucleotide polymorphisms [both coding for the apolipoprotein E (APOE) gene] were analyzed by Taqman real-time PCR (Applied Biosystems). Participants were divided into the APOE2 group (E2/2 and E2/3), E3 group (E3/3), or E4 group (E3/4 and E4/4). The E2/E4 genotype was excluded from grouping because opposite effects of the E2 and E4 alleles on CVD risk have been described previously (27) .
Statistics. Data are presented as means 6 SDs, unless otherwise indicated. Regarding serum lipid, lipoprotein, and lutein concentrations, kidney and liver function markers, and FFQ outcomes, changes were calculated between the end of the intervention period and baseline. An independent StudentÕs t test was performed to check for baseline differences and to test for differences in changes between the groups in the aforementioned variables. Differences in gender distribution and smoking status over the Egg and Con groups were tested by using the Pearson chi-square test.
Analysis of subgroups based on APOE genotypes and the ratio of campesterol to lathosterol (i.e., categorization into cholesterol synthesizers or absorbers) was performed by using ANOVA to evaluate differences between subgroups concerning lipids, lipoproteins, and lutein concentrations at baseline and at the end of the intervention upon lutein-enriched egg drink consumption. For this, BMI, gender, and age were considered as potential confounders because of their known interactions with cholesterol metabolism. Because these variables were equally distributed over the 3 APOE groups, we did not correct for them in this model. Thus, 1-factor ANOVA was used for evaluating differences between the APOE subgroups at baseline and changes upon lutein-enriched egg drink consumption. Gender and BMI were not equally distributed at baseline when the group was divided according to their campesterol-to-lathosterol ratio. Therefore, ANCOVA with gender and BMI as covariates was used to test for baseline differences and changes upon lutein-enriched egg drink consumption in between the low, mid, and high campesterol-to-lathosterol ratio groups. Post-hoc comparisons with Bonferroni correction were carried out to compare APOE groups and low, mid, and high campesterol-to-lathosterol ratio groups.
Statistical power calculation was initially based on MPOD because this was the primary outcome of this project (to be reported elsewhere). The expected increase in MPOD in this trial was estimated at 12%. Regarding an MPOD measuring error of 17%, a significance level (a) of 5%, a power of 90%, and a 10% drop-out rate, 48 participants had to be included in the study. However, for the secondary outcome parameter, flow-mediated dilation (FMD), 50 participants should be included in both intervention groups to detect a true difference in FMD of at least 1%, regarding an SD of FMD of 1.7%, a dropout rate of 10%, a power of 80%, and a = 5%. Therefore, a total of 101 participants started the study.
Statistical analyses were carried out by using an IBM SPSS Statistics 21.0 for Macintosh OS X package. Results were considered to be statistically significant if P < 0.05.
Results
Participant characteristics and dietary intake. At baseline, there were no differences between the Con and Egg groups regarding age, gender, smoking status, BMI, systolic blood pressure, diastolic blood pressure, glucose, hsCRP, and NEFAs. Also, baseline liver function variables were comparable between the groups, except for ALP concentrations, which were significantly higher (P < 0.05) in the Con group than in the Egg group ( Table 1) . This was due to relatively high ALP values in 3 participants compared with the total group, although these values were below the recommended upper limits for healthy liver function as established within the Maastricht University Medical Center+.
At baseline, total energy intake, proportion of energy from proteins, fats, and carbohydrates, and alcohol, fiber, and cholesterol intake were comparable between the 2 groups. During the intervention period, dietary cholesterol intake was higher in the Egg group than in the Con group (P < 0.001), which was anticipated because this was the targeted intervention. In addition, oleic acid intake was significantly lower in the Egg group (P < 0.05) ( Table 2) .
Plasma lutein and zeaxanthin. Baseline plasma lutein concentrations were comparable between the Egg and Con groups and also between men and women. Increases in plasma lutein and zeaxanthin concentrations were 83% and 110% higher in the Egg group than in the Con group (P < 0.001 and P < 0.01, respectively), which reflected good compliance. Gender-specific analysis revealed that these changes were evident in both men and women; however, increases in both lutein and zeaxanthin were more pronounced in men (127%; P < 0.01 and 110%; P < 0.05) than in women (77%; P < 0.01 and 45%; P < 0.05, respectively). In the Egg group, no significant differences at baseline and in change during the intervention between men and women were found.
Because lutein and zeaxanthin are transported by lipoproteins in the circulation, we also calculated the cholesterolstandardized plasma lutein concentrations to correct for changes in carrier capacity. After standardization of lutein for serum total cholesterol, an 83% higher increase in cholesterol-standardized lutein (P < 0.001) and a 50% higher increase in cholesterolstandardized zeaxanthin (P < 0.001) ( Table 3 ) was observed in the Egg group than in the Con group. This suggests that the conclusion is similar to the conclusion for nonstandardized lutein concentrations, and therefore, changes in lutein and zeaxanthin were not exclusively determined by changes in serum lipid and lipoprotein concentrations.
Serum lipids and lipoproteins. Baseline lipid and lipoprotein concentrations were comparable between the Egg and Con groups. No differences were found between the 2 groups regarding the change in serum total, LDL, and HDL cholesterol, the total-to-HDL cholesterol ratio, apoB100, apoAI, TGs, and NEFAs (Table 3) . Also, no differences were found in changes in serum lipids and lipoproteins throughout the intervention between men and women (data not shown). The expected increases in total, HDL, and LDL cholesterol and the total-to-HDL cholesterol ratio were calculated according to the prediction formula based on the meta-analysis by Weggemans et al. (4) . Interestingly, the measured changes in total, HDL, and LDL cholesterol after 12 mo were fully in line with these predictions, whereas the change in the total-to-HDL cholesterol ratio was lower than expected ( Table 4) . As shown in Supplemental Figure 1 , individual responses in total cholesterol concentration during the 1-y course of lutein-enriched egg drink consumption did not show remarkable differences between participants.
Markers for cholesterol metabolism and classification of responders and nonresponders. Cholesterol-standardized cholestanol, lathosterol, campesterol, and sitosterol serum concentrations are shown in Table 3 . No significant differences in change in these variables were observed throughout the intervention.
Next, the serum campesterol-to-lathosterol ratio was calculated to classify participants as being cholesterol synthesizers (low ratio) or cholesterol absorbers (high ratio). Participants were classified in tertiles having a low (#1.44), middle (1.45-1.66), or high ($1.67) campesterol-to-lathosterol ratio. Participants Effect of egg yolk dairy drink on serum lipids 1373 in the average (P < 0.05) or high (P < 0.01) group had a significantly higher baseline HDL cholesterol concentration than did participants with a low campesterol-to-lathosterol ratio, whereas other markers were not significantly different between these groups ( Table 5) . Baseline HDL cholesterol was 18% higher in the mid-ratio group (P < 0.05) and 21% higher in the high-ratio group (P < 0.05) than in the low-ratio group. This suggests that participants classified as being cholesterol absorbers might have a higher serum HDL cholesterol concentration than those classified as synthesizers. Interestingly, the change in HDL cholesterol upon lutein-enriched egg drink consumption was significantly different between the 3 campesterol-to-lathosterol ratio groups (P < 0.05). Although this significant change was found, post-hoc comparison could not reveal whether this could be attributed to the low, middle, or high campesterol-to-lathosterol ratio group. Only a trend toward a significantly higher increase in HDL cholesterol in the cholesterol absorbers than in the middle campesterol-tolathosterol ratio group was observed (P = 0.07), which might be caused by a lack of statistical power because of the small subgroups. In other words, the tertile with the highest baseline HDL cholesterol concentrations also had the highest increase in HDL cholesterol upon egg yolk consumption. Interestingly, the plasma lutein concentration in the high-ratio group was 229% higher than in the mid-ratio group (P < 0.05), whereas the plasma lutein concentration was 172% higher than in the low-ratio group (P = 0.08) ( Table 5 ).
The effect of APOE genotype on circulating lipid lipoprotein, lutein, and zeaxanthin concentrations. A total of 83 participants were included in analyzing the effect of APOE genotype on fasting lipids and carotenoids; DNA was collected from 87 participants, of whom 2 had the APOE2/4 genotype and were excluded from further analysis because of impossible classification in the APOE2, E3, or E4 groups (27) . We were unable to determine APOE genotype from 1 participant, and another participant was left out of the analysis because of outlying HDL cholesterol concentrations. The frequency distribution of the different genotypes in loci encoding APOE is shown in Supplemental Table 2 and was in line with that of the general population (27) . Baseline serum total and LDL cholesterol concentrations were respectively 23% (P < 0.05) and 22% (P < 0.05) lower in participants with the APOE2 genotype than in the APOE3 group (Supplemental Table 3 ). Supplemental Figure 2 shows the individual variation in baseline plasma lutein concentrations and the individual changes in plasma lutein concentrations after 1-y follow-up classified according to the different APOE groups. There were no significant differences in the mean changes in lipid, lipoprotein, or carotenoid concentrations between the 3 APOE genotypes during the lutein-enriched 
TABLE 4
Observed changes during a 1-y intervention with a lutein-enriched egg drink (n = 45) compared with placebo (n = 43) and expected changes based on prediction equations (4) in total, HDL, and LDL cholesterol concentrations and the total-to-HDL cholesterol ratio egg drink consumption (Supplemental Table 3 ). Results for differences in cholesterol-standardized lutein and zeaxanthin concentrations between groups based on the APOE genotype were essentially the same as those of absolute concentrations (data not shown).
Markers for kidney and liver function. Changes in kidney and liver function variables were monitored during the intervention to be able to observe any side effects. Apart from a greater increase in g-glutamyltransferase in the Con group than in the Egg group during the intervention (P < 0.05), no significant differences were found (data not shown). Most important, during the 1-y follow-up period, all liver and kidney function variables remained below the reference values as established within the Maastricht University Medical Center+.
Discussion
This study shows that the consumption of lutein-enriched egg yolk for a time period of 1 y leads to a significant increase in plasma lutein concentration. Both epidemiologic and intervention studies indicate that a higher lutein intake may delay AMD development (28, 29) . Because eggs are a known source of dietary lutein, we decided to investigate the effects of luteinenriched eggs on visual markers (to be reported elsewhere) and the possible side effects. An egg-containing beverage is well suited for a placebo-controlled trial because the control beverage can be adjusted for taste and color properties. Moreover, the bioavailability of lutein from eggs is known to be higher than from lutein supplements (11) . During this 1-y follow-up, serum total and LDL cholesterol increased in line with the available prediction equations (4); however, changes did not reach statistical significance. Based on different prediction models, the observed changes in serum lipids and lipoproteins imply a modest risk elevation. Whether the assumed beneficial effects on AMD outweigh the changed CVD risk deserves further analysis. Most importantly, we were able to identify a subpopulation of so-called cholesterol absorbers who presented themselves with significantly higher baseline HDL cholesterol concentrations and had a more pronounced increased plasma lutein concentration compared with participants categorized as cholesterol synthesizers based on their campesterolto-lathosterol ratio. In theory, this is regarded as the ideal target population for a lutein-enriched, egg yolk-containing dairy drink approach as a preventive strategy against AMD development.
The observed increase in plasma lutein concentrations during the 1-y daily lutein-enriched, egg yolk-containing drink consumption was in line with earlier short-term observations (30, 31) . This suggests that there is a plateau in serum lutein concentrations after interventions with a shorter duration of 4-12 wk (30), obviously depending on the quantity and form of lutein supplementation. Although our lutein-enriched dairy drink contained less lutein (1.5 mg per serving) in comparison with conventional supplements (10-20 mg), the lipid matrix in which the lutein was provided was shown to increase its bioavailability (32) . The 83% increase in plasma lutein concentrations resulted in a mean plasma lutein concentration of 399 mg/L. Previously, Berendschot et al. (30) showed a stabilized serum lutein concentration of ;340 mg/L after 4 wk of 10-mg lutein supplementation in a comparable population. From these results, we can conclude that supplementation of lutein via lutein-enriched egg yolks incorporated into a buttermilk drink is at least as efficient in increasing plasma lutein concentrations as supplementation via supplements because much lower quantities of lutein are needed to reach comparable plasma lutein concentrations. Whether this translates into increased MPOD values and slows down the regression of AMD needs further study (manuscript in preparation).
An important issue related to the use of an egg yolk matrix that needs to be addressed is how daily consumption of 1.5 egg yolks translates into changes in CVD risk. Although the observed increases in total and LDL cholesterol were not significant, they were fully in line with the expectations according prediction equations by Weggemans et al. (4) . These predictions are based on studies with a maximum intervention duration of 20 wk. Based on our data, we can conclude that cholesterol metabolism has clearly reached a new steady state already after these 20 wk because changes in serum cholesterol concentrations as observed after 1-y follow-up are comparable to the prediction outcome ( Table 4 ). The question of what the observed changes in serum lipids and lipoproteins mean in terms of CVD risk prediction is highly relevant given the ongoing discussion regarding the need for restriction of egg consumption in the dietary guidelines. The outcome of future CVD risk prediction depends on whether changes in LDL cholesterol or changes in the total-to-HDL cholesterol ratio are used. A 1-mmol/L decrease in LDL cholesterol concentrations is associated with a 20% lowering in risk of coronary events such as myocardial infarction and ischemic stroke (33, 34) . If one would translate this curve-linear relation from the included Effect of egg yolk dairy drink on serum lipids 1375 pharmaceutical trials to the results from our dietary intervention study (an increase in LDL cholesterol of 0.14 mmol/L), if this were significant, one would assume a modest increase in risk of coronary events of 2.8%. However, the observed decrease in the total-to-HDL cholesterol ratio is related to a 0.7% decrease in risk of future coronary heart disease (35) . Moreover, a strong correlation between the change in apoB100 and LDL cholesterol concentrations (r = 0.822, P < 0.001) was found in the present study. This is in line with studies that showed a parallel relation between change in apoB100 concentration and LDL cholesterol concentrations (36) (37) (38) (39) , and implies that there is no change in the amount of cholesterol per LDL particle. In other words, there is apparently no change in LDL particle size or density. Previous studies suggested that egg consumption shifts the LDL fraction toward the less atherogenic LDL-1 subclass (40). We could not confirm this suggestion, however, after studying the consumption of a lutein-enriched egg drink for 1 y. Next, we explored the effect of consuming the lutein-enriched egg drink on markers for cholesterol metabolism, i.e., markers for endogenous cholesterol synthesis and fractional intestinal cholesterol absorption. Previous short-term studies did not show an effect on these markers after consumption of 1 additional egg yolk/d for 12 wk (41). We confirm our prior observation by showing that these markers are not affected after 1-y additional daily mean intake of 323-mg dietary cholesterol provided through 1.5 egg yolks. However, one should consider that using lathosterol as a marker for endogenous synthesis in egg consumption may not be ideal because egg yolks have been suggested as a lathosterol-rich source (42) . It is generally accepted that there is a large interindividual variation in dietary cholesterol absorption ranging between 20% and 70% (19) . In addition, participants can be classified as being cholesterol absorbers or synthesizers (20) . An individual with a high campesterol-to-lathosterol ratio identifies as a cholesterol absorber, whereas a low ratio classifies a so-called synthesizer (21) . Based on this classification, we attempted to see whether we could identify more or less responsive subgroups, both in lutein and lipid and lipoprotein concentrations. In this study, we show that the so-called cholesterol absorbers had significantly higher baseline HDL cholesterol concentrations. In addition, these participants also had a higher increase in serum HDL cholesterol and significantly higher serum lutein concentrations after 1-y egg yolk consumption than did cholesterol synthesizers and participants in the mid campesterol-to-lathosterol ratio group. From this, we conclude that cholesterol absorbers might benefit most from the lutein-enriched egg yolk drink, not only because serum lutein increase was most pronounced, but also because serum HDL cholesterol concentrations increased significantly. Importantly, no significant differences in change in LDL cholesterol or the total-to-HDL cholesterol ratio between the 3 subgroups were observed. It is important to realize that the change in LDL cholesterol in the absorbers, if this change were significant, corresponds to a 4.4% increase in risk of future CVD, whereas the increase in total-to-HDL cholesterol ratio relates to a 1.0% increase in this risk. Both of these are slightly higher than calculated in the entire population. Although this risk of cardiovascular events cannot be outweighed, we need to point out that the egg yolk-based buttermilk drink provided in this intervention study was enriched with highly bioavailable lutein, which might be beneficial to (cardiovascular) health (43) .
A second typical example of such a subgroup could be based on the APOE genotype because the relation between apoE and cholesterol metabolism is well known (27, 44) . Moreover, a pooled analysis of data from studies evaluating the relation between the APOE genotype and AMD provided evidence for a protective role of the e4 haplotype in AMD and a significant increased risk associated with the e2e2 diplotype for late AMD. Additionally, it is well known that the e4 isoform predisposes to higher intestinal cholesterol absorption efficiency, whereas the e2 isoform is associated with lower fractional intestinal cholesterol absorption (24) . This would be an ideal condition for the development of personalized nutrition strategies using the lutein-enriched egg yolk drink because the APOE2 group is characterized by low plasma lutein concentrations and at the same time this group is not expected to respond as strongly with an increase in total cholesterol or LDL cholesterol concentrations. However, possibly resulting from the relatively small sample size in this subanalysis, we conclude that, in contrast to the campesterol-to-lathosterol ratio, the APOE genotype cannot be used as a subgroup classification to identify luteinresponsive subgroups, based on the present results. Further studies using a larger sample size are needed to confirm this hypothesis.
In conclusion, consuming lutein-enriched egg yolks incorporated into a buttermilk drink daily for a time period of 1 y resulted in a significantly increased plasma lutein concentration, without significantly increasing lipid or (apo)lipoprotein concentrations. A subgroup that potentially benefits most from the lutein-enriched egg drink approach is participants characterized as cholesterol absorbers. They had a larger increase in HDL cholesterol during the intervention, notwithstanding their already higher baseline HDL cholesterol concentrations, and at the same time responded with a more pronounced increase in plasma lutein concentration.
